Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Galectin names Thomas McGauley acting CFO

This article was originally published in Scrip

Executive Summary

Galectin Therapeutics, a company developing therapies for cancer and fibrotic disease, has appointed Thomas McGauley acting chief financial officer replacing Anthony Squeglia. Mr McGauley will serve in this role until 30 September 2012 when a permanent CFO can be found. He has been the company's director of finance and accounting since 2009, and until 2010 was director of financial reporting at deCODE genetics. He previously worked in public accounting for companies including PricewaterhouseCoopers, where he specialised in life sciences.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC016578

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel